Exosome Therapy Regulation in the UK: A Reference

The short regulatory position

“Exosome therapy” is a treatment description, not a UK regulatory category. A clinic cannot establish the legal status of a particular product merely by calling it cell-free, regenerative, topical, injectable or cosmetic. The relevant question is what the product is, how it is made, what is said about it and how it is intended to act or be used.

The Medicines and Healthcare products Regulatory Agency, commonly called the MHRA, is central where a product may be a medicine or medical device. Its published guidance explains that classification depends on the individual product and its intended purpose. A medicine generally requires a marketing authorisation before it is placed on the market, subject to limited legal routes and exceptions that are not a general permission to promote an unapproved treatment.

The Human Tissue Authority has a separate remit over specified activities involving human tissue. The Advertising Standards Authority applies advertising rules, including the CAP Code for non-broadcast advertising. None of those bodies gives a general approval to the phrase “exosome therapy”.

This distinction matters for a reader presented with a treatment proposal. A practitioner may be able to describe a procedure, but that does not answer whether the product has a marketing authorisation, whether its claims are acceptable, whether human material was handled within the applicable framework, or whether the practitioner can justify offering it. The safe starting point is to ask for product-specific answers in writing.

For background on vesicle science and grading, use the separate reference on exosome biology and grading. This page concerns the regulatory questions that follow when such material is offered to a patient.

What the MHRA decides, and what it does not

The MHRA regulates medicines and medical devices in the UK. Its role is especially relevant when a proposed product is presented as preventing, treating or diagnosing disease, or when it is said to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action. Presentation and claims can be as important as composition. A product described in promotional material as stimulating hair growth or repairing damaged skin may therefore raise a medicines classification question.

A medical device is assessed through a different framework. In broad terms, a device’s principal intended action is not achieved by pharmacological, immunological or metabolic means, although it may be assisted by such means. The label on a vial, the route of administration and a practitioner’s verbal explanation do not themselves settle that distinction. The MHRA can consider borderline products case by case.

Cosmetics have a narrower purpose. They are intended to be applied to external parts of the body, teeth or mucous membranes mainly to clean, perfume, change appearance, protect, keep in good condition or correct body odours. A cosmetic cannot be used as a regulatory shelter for medicinal claims. An injection is also not simply made cosmetic by describing its intended result as rejuvenation.

Ask the clinic to identify the exact product, its manufacturer, its stated intended purpose and the regulatory route it says applies. If it says the product is authorised as a medicine, ask for the marketing authorisation details. If it says it is a device, ask what conformity and registration information is relevant. If it says it is neither, ask for a clear written explanation of why that classification is said to be appropriate.

Human-derived material and the Human Tissue Authority

The Human Tissue Authority, or HTA, regulates particular activities involving human tissue under the Human Tissue Act framework. Its remit is not a product endorsement scheme and an HTA licence, where one is required, does not mean that a finished product is authorised by the MHRA as a medicine. These are separate questions with separate legal purposes.

Whether HTA requirements apply depends on the material and the activity. Relevant issues can include procurement, storage, use, traceability and consent, as well as whether material falls within the statutory definitions and exemptions. A clinic should not imply that a broad statement such as “donor screened” or “tissue compliant” resolves every regulatory question about a product derived from human material.

A reader need not decide the legal analysis alone. It is reasonable to ask whether the proposed product is human-derived, what type of source material is involved, whether the clinic or its supplier considers HTA licensing relevant, and which organisation is responsible for that assessment. Ask for the answer in writing and for the identity of the legal manufacturer or supplier. A refusal to identify the product’s source or the organisation responsible for placing it on the market makes meaningful regulatory checking difficult.

Do not treat traceability language as proof of clinical effectiveness. Equally, do not treat a discussion of research consent or tissue handling as proof that a product has a marketing authorisation. The HTA’s function concerns the lawful and appropriate handling of relevant human material. The MHRA question concerns the regulatory status of a product and the claims made for it.

Advertising rules and claims for unlicensed treatments

The Advertising Standards Authority administers the CAP Code for non-broadcast advertising. Its rules require marketing communications to be legal, decent, truthful and prepared with a sense of responsibility. Health and beauty claims need adequate substantiation. In practice, a persuasive testimonial, a striking before-and-after image or a practitioner’s assurance does not replace suitable evidence for a treatment claim.

The CAP Code also contains specific rules for medicines, medical devices and health claims. Advertising must not mislead consumers about a product’s status, safety or efficacy. Advertisers must be able to support objective claims, and advertising for medicinal products is subject to further restrictions. Where a treatment is not authorised as a medicine, advertising should not create the impression that it has a regulatory approval it does not hold.

Look beyond the word “advert”. A clinic website, social-media post, consultation handout, email campaign and paid search page can all be marketing communications. The relevant claim may be implied rather than stated outright. “Clinically proven”, “regenerative”, “repairs follicles”, “reverses thinning” and “risk-free” each carry implications that require careful support and context.

Ask for the evidence behind the particular outcome claimed for your indication, route and product. Ask whether the same wording has been reviewed for CAP Code compliance. A clinic does not have to provide a legal opinion, but it should be able to distinguish an aspirational description from a claim it can substantiate. The Advertising Standards Authority can assess advertising, but it does not authorise a treatment for clinical use.

Professional duties when there is no marketing authorisation

The absence of a marketing authorisation does not by itself answer every question about a proposed intervention, but it raises the standard of explanation a patient should expect. A practitioner must work within their competence, scope of practice and applicable professional standards. They must be able to explain why the treatment is proposed for the individual, what is known and not known, what alternatives exist, and what will happen if complications or unexpected outcomes occur.

Valid consent is a process, not a signed page. For a treatment without a marketing authorisation, meaningful consent should not be built on vague language such as “advanced”, “natural” or “cutting-edge”. It should distinguish research interest from established clinical benefit, identify material uncertainties, state whether the proposed use is outside an authorised indication or involves a product without a marketing authorisation, and allow time for questions without pressure to proceed.

Ask who will perform the assessment, who will administer the product, who will provide aftercare and who accepts responsibility if you need urgent review. Ask what adverse-event records are kept and what reporting route would be used if a suspected medicine or device safety issue arose. These questions concern accountability, not merely bedside manner.

A practitioner should not allow a commercial consultation to substitute for an assessment of suitability. Read this publication’s page on who should not have exosome therapy before consenting, and use the editorial policy page to understand how this reference treats evidence and uncertainty. Neither page replaces individual clinical advice.

A screenshot rule: match the claim to the regulator

The table below is a practical map rather than a legal determination. It separates common treatment indications from the regulatory question that can actually be answered. The study-design column deliberately does not rate evidence: the named regulators do not establish clinical efficacy by assigning a preferred study design to each aesthetic indication. For appraisal of research reports, use this publication’s study quality review.

Decision rule: do not proceed on the basis of a treatment name. First obtain the product identity and intended claim. Then match product status to the MHRA, human-material handling to the HTA where relevant, and public claims to the Advertising Standards Authority and CAP Code. If those answers cannot be separated, pause rather than treating a broad assurance as evidence.

Documents and answers a clinic should be able to provide

A patient cannot demand every confidential manufacturing document, but a clinic asking for consent should be able to provide enough information for the patient to understand what is being offered. The minimum useful record is specific. It names the product, identifies the organisation responsible for it, states the proposed route of administration and sets out the intended purpose without relying on slogans.

• The exact product name, manufacturer or legal supplier, batch identification where appropriate, and the proposed route of use.
• A written explanation of the claimed regulatory status, including whether the clinic says it is a medicine, medical device, cosmetic or another category.
• Marketing authorisation details if the product is said to be an authorised medicine, or a clear explanation that no such authorisation is claimed.
• The basis on which any human-derived material is said to have been procured and handled within the applicable framework, including whether HTA requirements are said to apply.
• The evidence supporting the precise outcome claimed for the intended use, separated from general laboratory discussion or unrelated procedures.
• A consent document that identifies material uncertainty, risks, alternatives, aftercare arrangements and the responsible practitioner.
• An explanation of how advertising claims have been framed so that they do not overstate regulatory status or likely outcomes.

These are questions for a consultation, not accusations. A clear answer may reveal that a proposed claim is more limited than the marketing suggested. An unclear answer is itself relevant to a decision about whether the consultation has supplied enough information for consent.

Limits of this reference

This is a UK regulatory orientation, not legal advice, a product classification decision or medical advice. It does not decide the status of a named vial, supplier or clinic. The MHRA can assess classification on the facts of an individual product, and the application of human tissue rules can turn on details that are not visible in consumer-facing material.

This page does not assess whether exosome therapy works for hair loss, skin concerns, wound healing or any other purpose. It does not compare clinical outcomes with platelet-rich plasma, polynucleotides or other interventions. It also does not cover device settings or procedural detail for radiofrequency microneedling. Those are different questions from whether claims and products have been properly identified.

The reference applies to people considering treatment in the United Kingdom or assessing advertising directed at UK consumers. It may not apply to products obtained abroad, research conducted under a separate governance structure, or non-UK advertising rules. Regulatory requirements can change, and a historic webpage or brochure may not reflect the current position.

If a product is presented as having an MHRA status, HTA basis or advertising clearance, verify the statement against the relevant body’s published guidance and ask the provider to explain how that guidance applies to the exact product and claim. Do not assume that a regulator’s remit over one part of the pathway validates the whole treatment proposition.

Disclosure. This article names a business and links to its website. This publication and that website are managed by the same group, which is a commercial relationship. The business did not write or approve the article, and it is named because it is relevant to the subject.